Literature DB >> 12072160

The role of T-type calcium channels in morphine analgesia, development of antinociceptive tolerance and dependence to morphine, and morphine abstinence syndrome.

Ahmet Dogrul1, Unal Zagli, F Cankat Tulunay.   

Abstract

Involvement of T-type voltage dependent Ca2+ channels (VDCCs) on morphine antinociception, in the development of tolerance and dependence to morphine, and naloxone-precipitated abstinence syndrome in morphine dependent mice was examined by using mibefradil, a T-type VDCCs blocker. Mice were rendered tolerant and dependent on morphine by subcutaneous (s.c.) implantation of a morphine pellet containing 75 mg of morphine base for 72 hr. The tail-flick test was used to assess the nociceptive threshold. Coadministration of acute mibefradil (10 mg/kg, i.p.) with morphine enhanced the antinociceptive effects of acute morphine. Repeated mibefradil administration (10 mg/kg, i.p., just before, 24 and 48 hr after morphine pellet implantation) completely blocked the development of tolerance to the antinociceptive effect of morphine and even by this effect reached supersensitivity to morphine. However, repeated mibefradil treatment did not alter the development of dependence to morphine assessed by the A(50) values of naloxone (s.c.) required to precipitate withdrawal jumping 72 hr after morphine pellet. But, acute mibefradil (10, 30, and 50 mg/kg, i.p.) dose dependently decreased the expression of morphine abstinence syndrome when given directly 30 min prior to naloxone (0,05 mg/kg, s.c.) 72 hr after morphine pellet. These results indicate a critical role of T-type VDCCs in morphine antinociception, the development of tolerance to the antinociceptive effects of morphine and in morphine abstinence syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072160     DOI: 10.1016/s0024-3205(02)01736-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

Review 1.  Low-voltage-activated ("T-Type") calcium channels in review.

Authors:  Anne Marie R Yunker; Maureen W McEnery
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

Review 2.  Modulation and pharmacology of low voltage-activated ("T-Type") calcium channels.

Authors:  Anne Marie R Yunker
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

3.  T-type channels control the opioidergic descending analgesia at the low threshold-spiking GABAergic neurons in the periaqueductal gray.

Authors:  Cheongdahm Park; Jong-Hyun Kim; Bo-Eun Yoon; Eui-Ju Choi; C Justin Lee; Hee-Sup Shin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-03       Impact factor: 11.205

4.  Effect of potassium channel modulators on morphine withdrawal in mice.

Authors:  Vikas Seth; Mushtaq Ahmad; Prerna Upadhyaya; Monika Sharma; Vijay Moghe
Journal:  Subst Abuse       Date:  2010-11-16

5.  Pharmacological Inhibition of Voltage-gated Ca(2+) Channels for Chronic Pain Relief.

Authors:  Seungkyu Lee
Journal:  Curr Neuropharmacol       Date:  2013-12       Impact factor: 7.363

6.  Opioid dependence and substitution therapy: thymoquinone as potential novel supplement therapy for better outcome for methadone maintenance therapy substitution therapy.

Authors:  Liyana Hazwani Mohd Adnan; Nor Hidayah Abu Bakar; Nasir Mohamad
Journal:  Iran J Basic Med Sci       Date:  2014-12       Impact factor: 2.699

7.  Attenuation of morphine tolerance and dependence by thymoquinone in mice.

Authors:  Hossein Hosseinzadeh; Siavash Parvardeh; Alireza Masoudi; Mahsa Moghimi; Fatemeh Mahboobifard
Journal:  Avicenna J Phytomed       Date:  2016 Jan-Feb

8.  Association between genetic polymorphisms in Ca(v)2.3 (R-type) Ca2+ channels and fentanyl sensitivity in patients undergoing painful cosmetic surgery.

Authors:  Soichiro Ide; Daisuke Nishizawa; Ken-ichi Fukuda; Shinya Kasai; Junko Hasegawa; Masakazu Hayashida; Masabumi Minami; Kazutaka Ikeda
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

9.  Role of calcium in morphine dependence and naloxone-precipitated withdrawal in mice.

Authors:  Vikas Seth; Prerna Upadhyaya; Vijay Moghe; Mushtaq Ahmad
Journal:  J Exp Pharmacol       Date:  2011-02-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.